高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价

doi:10.11904/j.issn.1002-3070.2022.02.008

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (2): 144-149.doi: 10.11904/j.issn.1002-3070.2022.02.008

高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价

胡宗涛¹, 刘演¹, 高世乐², 甘晨¹, 张永康¹

1.中国科学院合肥肿瘤医院放疗部(合肥 230031);
2.中国人民解放军联勤保障部队第九〇一医院肿瘤四科

收稿日期:2021-08-31 修回日期:2022-01-07 出版日期:2022-04-28 发布日期:2022-04-28
通讯作者: 胡宗涛,E-mail:huxuyan@163.com
作者简介:胡宗涛,男,(1971-),硕士,副主任医师,从事晚期胰腺癌个体化治疗的研究。
基金资助:
安徽省重点研究与开发计划项目(编号:201904a07020104)

The clinical efficacy and safety evaluation of high-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy in patients with locally advanced pancreatic cancer

HU Zongtao¹, LIU Yan¹, GAO Shile², GAN Chen¹, ZHANG Yongkang¹

1. Department of Radiotherapy,Hefei Cancer Hospital,Chinese Academy of Sciences,Hefei 230031,China;
2. Department of Oncology,Four Ward,No.901 Hospital,Support Force of the Chinese People′s Liberation Army

Received:2021-08-31 Revised:2022-01-07 Online:2022-04-28 Published:2022-04-28

摘要/Abstract

摘要： 目的研究高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及治疗相关不良反应。方法选取2018年9月—2020年11月中国科学院合肥肿瘤医院收治的72例局部晚期胰腺癌患者,分为对照组36例和实验组36例,对照组患者给予白蛋白结合型紫杉醇、替吉奥方案化疗,实验组患者在对照组基础上,给予胰腺癌病灶高剂量少分次放疗。最终对照组入组34例,实验组入组33例。观察两组患者总生存期(OS)、无进展生存期(PFS)、客观有效率(ORR)、疾病控制率(DCR)以及治疗相关不良反应发生率。结果实验组患者中位OS和中位PFS分别为12.4个月和6.3个月,长于对照组的8.5个月和4.2个月(P＜0.05);ORR为21.21%,虽高于对照组的5.88%,但差异无统计学意义(P＞0.05);DCR为66.67%,高于对照组的38.24%(P＜0.05);血清CEA、CA19-9、CA724和CTC表达水平均显著低于对照组(P＜0.05)。两组患者乏力、肝功能损伤、骨髓抑制、感觉神经毒性和关节痛/肌肉痛不良反应发生率差异无统计学意义(P＞0.05);实验组患者胃肠反应发生率高于对照组(P＜0.05),但可控可耐受。结论高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中临床疗效显著,有效延长生存期,治疗相关不良反应可控,值得临床推广。

关键词: 适形, 剂量分割, 白蛋白结合型紫杉醇, 替吉奥, 胰腺肿瘤, 治疗效果

Abstract: Objective The aim of this study was to study the clinical efficacy and treatment-related adverse reactions of high-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy in patients with locally advanced pancreatic cancer. Methods A total of 72 locally advanced pancreatic cancer patients who were admitted to Hefei Cancer Hospital of Chinese Academy of Sciences from September 2018 to November 2020 were selected and divided them into the control group of 36 cases and experimental group of 36 cases.The patients in the control group were given chemotherapy with nab-paclitaxel and Sigiroid, and the patients in the experimental group were given high-dose and less-fractionated radiotherapy for pancreatic cancer on the basis of the control group. Finally, 34 cases in the control group and 33 cases in the experimental group were included. The overall survival(OS), progression-free survival(PFS), Objective response rate(ORR), disease control rate(DCR), and incidence of treatment-related adverse reactions were observed. Results The median OS and median PFS of the experimental group were 12.4 months and 6.3 months,respectively, which were longer than 8.5 months and 4.2 months in the control group(P＜0.05); the ORR was 21.21%,although higher than that in the control group(5.88%), but the difference is not statistically significant(P＞0.05); DCR was 66.67%, which was higher than that in the control group(38.24%)(P＜0.05); the levels of serum CEA, CA19-9,CA724 and CTC were significantly lower than those of the control group(P＜0.05). There was no significant difference in the incidence of fatigue,liver function damage,bone marrow suppression, sensory neurotoxicity, and pain/myalgia adverse reactions between the two groups(P＞0.05); the incidence of gastrointestinal reactions in the experimental group was higher than that in the control group(P＜0.05); but they were controllable and tolerable. Conclusion High-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy have significant clinical effects on patients with locally advanced pancreatic cancer, effectively prolonging survival period, and controllable treatment-related adverse reactions, which is worthy of clinical promotion.

Key words: Conformity, Dose-fractionation, Albumin-bound paclitaxel, Tiggio, Pancreatic neoplasms, Therapeutic effect

中图分类号:

R735.9

胡宗涛, 刘演, 高世乐, 甘晨, 张永康. 高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价[J]. 实用肿瘤学杂志, 2022, 36(2): 144-149.

HU Zongtao, LIU Yan, GAO Shile, GAN Chen, ZHANG Yongkang. The clinical efficacy and safety evaluation of high-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy in patients with locally advanced pancreatic cancer[J]. Journal of Practical Oncology, 2022, 36(2): 144-149.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.02.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I2/144

参考文献

1 Sung H,Ferlay J,Siegl RL,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Grossberg AJ,Chu LC,Deig CR,et al.Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma[J].CA Cancer J Clin,2020,70(5):375-403.
3 李珊,赵春波,乔文波.术中放疗在胰腺癌中的应用进展[J].实用肿瘤学杂志,2019,33(3):280-283.
4 Singhi AD,Koay EJ,Chari ST,et al.Early detection of pancreatic cancer:Opportunities and challenges[J].Gastroenterology,2019,156(7):2024-2040.
5 Yang JH,Xu J,Zhang B,et al.Ferroptosis:at the crossroad of gemcitabine resistance and tumorigenesis in pancreatic cancer[J].Int J Mol Sci,2021,22(20):1-16.
6 钱元,郑松.改良FOLFIRINOX方案治疗进展期胰腺癌的疗效及安全性[J].临床肿瘤学杂志,2018,23(11):1017-1022.
7 Guo X,Xu YL,Ji Y,et al.Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer[J].Int J Pancreatol,2020,3(1):35-41.
8 Loehrer PJ Sr,Feng Y,Cardens H,et al.Gemcitabine alone versus gemeitabine plus radiotherapy in patients with locally advanced pancreatic cancer:an Eastern Cooperative Oncology Group trial[J].J Clin Oncol,2011,29(31):4105-4112.
9 张韬,腾以娟,纪少春.局部晚期胰腺癌聚焦大分割适形放疗的临床研究[J].医学信息,2018,31(14):101-103,106.
10 秦青,任刚,李晶,等.高剂量少分次放疗模式治疗胰腺癌对患者生活质量的影响[J].中华放射肿瘤学杂志,2018,27(7):656-660.
11 Wahl RL,Jacene H,Kasamon Y,et al.From RECIST to PERCIST:Evolving Considerations for PET Response Criteria in Solid Tumors[J].J Nucl Med,2009,50(Suppl 1),122s-150s.
12 赵旭东,马永蔌,田孝东.胰腺癌循环肿瘤细胞检测及临床应用进展[J].中华外科杂志,2019,57(5):393-396.
13 Motoaki S,Suguru O,Ryo Y,et al.A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100[J].Asia Pac J Clin Oncol,2020,16(1):80-85.
14 马少军,张秀军,曹洪波.胰腺癌微环境研究进展[J].中国中西医结合外科杂志,2019,25(3):407-410.
15 Yu JM,Ding ZY,Yang YM,et al.Increased platelet-to-lymphocytes ratio is associated with poor long-term prognosis in patients with pancreatic cancer after surgery[J].Medicine,2018,97(25):e11002.
16 周昌明,高鹤丽,石燕.PRODIGE 24-ACCORD研究解读[J].中国癌症杂志,2019,29(5):379-389.

[1]	杨东明, 卢庆刚. “半野”三维适形放疗、固定野静态调强放疗和容积旋转调强放疗在中晚期宫颈癌治疗上的剂量学比较[J]. 实用肿瘤学杂志, 2020, 34(3): 244-248.
[2]	杨磊, 苏丹, 娄长杰. 肝胆胰恶性肿瘤患者在新型冠状病毒肺炎疫情期间及疫情过后的诊治思考与建议[J]. 实用肿瘤学杂志, 2020, 34(2): 107-110.
[3]	康振国, 纪卫政, 顾俊鹏, 朱帝文, 张海潇, 任伟新. 肝癌射频消融术后联合替吉奥节拍化疗的疗效评价[J]. 实用肿瘤学杂志, 2016, 30(1): 17-22.
[4]	孙迪, 云惟康, 葛晓峰, 陈林, 胡洪涛. 局部晚期喉癌3DCRT与IMRT放疗计划的剂量学对比[J]. 实用肿瘤学杂志, 2015, 29(5): 420-423.
[5]	燕小飞(综述),韩波(审校). 局部晚期鼻咽癌的治疗现状及展望[J]. 实用肿瘤学杂志, 2015, 29(2): 149-152.
[6]	刘世伟,孙迪,邢宝继,王林海. 容积旋转调强技术在宫颈癌术后放疗中的应用[J]. 实用肿瘤学杂志, 2014, 28(5): 435-438.
[7]	张一君, 邹天宁, 陈杨萍, 陈艳. 乳腺癌新辅助化疗疗效评价及预测的研究进展[J]. 实用肿瘤学杂志, 2011, 25(5): 477-481.
[8]	徐建宇, 徐向英, 许庆勇, 胡松柳, 刘珊珊, 卢姗. 局部晚期非小细胞肺癌不同放化疗模式的临床研究[J]. 实用肿瘤学杂志, 2010, 24(1): 48-52.
[9]	冯志刚, 郭建文, 班新能, 山长平, 魏江萍, 殷晓娟, 刘长龙, 龚耀. 三维适形放疗联合奈达铂与5-Fu方案治疗进展期食管癌疗效分析^△[J]. 实用肿瘤学杂志, 2009, 23(6): 545-547.
[10]	夏炎春, 杨建舟, 周诚忠, 宋永浩, 夏海波, 张力彬. 老年人非小细胞肺癌三维适形放疗的疗效分析[J]. 实用肿瘤学杂志, 2009, 23(5): 454-455.
[11]	卢秋霞, 卫光宇, 唐溢聪, 魏伟宏. 148例鼻咽癌肝转移的治疗与预后分析[J]. 实用肿瘤学杂志, 2009, 23(4): 314-318.
[12]	栾瑾微, 尤庆山. 不同方法治疗晚期胰腺癌的临床疗效观察[J]. 实用肿瘤学杂志, 2009, 23(4): 328-331.
[13]	马景光, 邢丽娜, 刘晓, 董广璐, 刘晓滨, 魏星. 卡培他滨联合奈达铂同步放化疗宫颈复发癌[J]. 实用肿瘤学杂志, 2009, 23(4): 346-348.
[14]	纪卫;张献南;胡建军. 三维适形放疗联合动脉灌注化疗治疗局部晚期胰腺癌的临床疗效观察[J]. 实用肿瘤学杂志, 2008, 22(03): 272-274.
[15]	郭化东;姜秀玲;石磊;王滨. 颅内胶质瘤的立体定向放射治疗[J]. 实用肿瘤学杂志, 2007, 21(04): 363-365.

高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价

The clinical efficacy and safety evaluation of high-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy in patients with locally advanced pancreatic cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价